BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

Powered by Business Wire
Research and Science Headlines

Blade Therapeutics to Present at the Stifel 2017 Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs, today announced that Wendye Robbins, M.D., President, Chief Executive Officer, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 1:15 p.m. Eastern Time. The conference will be held at the Lotte New York Palace Hotel in New York.

About Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade has assembled a critical mass of fibrosis expertise and a top-tier leadership team and world-class network of advisors with unparalleled experience in anti-fibrotic drug R&D. Blade ’s lead program is a small molecule inhibitor targeting an intracellular cysteine protease that has been shown to be associated with fibrosis across diverse indications. The Company anticipates entering the clinic with its lead development candidate in mid-2018. For its foundational programs, Blade is leveraging insights from Johns Hopkins University School of Medicine (Laboratory of Hal Dietz, M.D.) to discover new therapeutic approaches that can broadly modulate fibrosis, and thereby contribute to the treatment of diverse diseases. Lead investors in Blade include MPM Capital, Deerfield, Osage Partners, as well as the venture funds of Pfizer, Bristol-Myers Squibb, and Novartis.

Please visit http://www.blademed.com/ for more information.

Contacts

Blade Therapeutics
Wendye Robbins, M.D., President and CEO
wrobbins@blademed.com
or
Felix Karim, Ph.D., Executive Vice President, Business Development
650-278-4291
or
Burns McClellan, Inc.
Jill Steier, VP, Investor Relations
jsteier@burnsmc.com
212-213-0006